EBTATE

EBTATE is a patented long-acting peptide receptor radionuclide therapy (PRRT) developed by Molecular Targeting Technologies. It consists of a somatostatin analog (octreotide) conjugated to the radioisotope lutetium-177 via the chelator DOTA and an Evans blue derivative. The Evans blue moiety binds to serum albumin, significantly extending the drug’s circulatory half-life and tumor residence time. This design enables enhanced tumor uptake—up to 30-fold higher than standard therapies—and allows for lower and less frequent dosing compared to current standards like 177Lu-DOTATATE[1][2][5][7]. The primary mechanism involves selective binding to somatostatin receptor type 2 (SSTR2), which is overexpressed on neuroendocrine tumors. Once bound, the radiolabeled compound delivers targeted ionizing radiation directly to malignant cells[1][5][7]. Preclinical and early clinical studies have shown that both lutetium-labeled (177Lu) and actinium-labeled (225Ac) versions are effective against SSTR2-positive neuroendocrine tumors as well as small cell lung cancer models[2][6]. Clinical data indicate good safety with no significant nephrotoxicity or hepatotoxicity at reduced doses compared with existing PRRT agents[6].

Brand names

EBTATE

Other names

225Ac-EBTATE (for actinium-labeled version)EvaThera drug (as referenced in some materials)